Company Name:Avrobio, Inc.
CEO: Geoff MacKay

Sector: Health Technology

Exchange: NASDAQ

Country: US

Description: Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firms clinical-stage programs include Fabry disease, Gaucher disease and cystinosis . The company was founded by Geoff Mackay in 2015 and is headquartered in Cambridge, MA.

Key numbers

Market Capitalization:641071545
Shares Outstanding: 36035500
Float: 29161008
Next Earning Date:2020-08-06
TTm EPS: -2.7215
TTm Dividend Rate:
200 days moving average:17.82
50 days moving average: 19.43
One day percent Change: -5.94

2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2016-12-31, 2017-12-31, 2018-12-31,
2016-12-31, 2017-12-31, 2018-12-31,